GTR Home > Tests > HER2 FISH analysis

Overview

Test order codeHelp: 003019

Test name

Help

HER2 FISH analysis

Purpose of the test

Help

This is a clinical test intended for Help: Diagnosis, Drug Response, Monitoring, Prognostic, Therapeutic management

Condition

Help

Loading data ......

Click Indication tab for more information.

How to order

Help

Complete requisition form
Order URL Help: http://www.genetix.com.co/

Specimen source

Peripheral (whole) blood
Specimen requirements: http://www.genetix.com.co/

Methodology

Help
Cytogenetics
IFISH-interphase
Fluorescent in situ hybridization
  • None/not applicable

Summary of what is tested

Loading data ......

Click Methodology tab for more information.

Clinical utility

Help

Guidance for management

Citations
  • Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. - PubMed ID: 24267730
  • Eur J Cancer. 2013 Nov 21. doi:pii: S0959-8049(13)00904-0. 10.1016/j.ejca.2013.10.004

Clinical validity

Help

Control probes are used in each case.

Citations

Not provided

Testing strategy

Help

Fluorescent in situ hybridization of HER. Normal controls used at the same time. 000 Complete requisition form

Test services

Help
  • Clinical Testing/Confirmation of Mutations Identified Previously
  • Genetic counseling

Suggested reading

  • Cardoso et al., 2016
  • Ward et al., 2013
    Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.

Clinical resources

Practice guidelines

  • NICE, 2024
    UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024
  • NCCN, 2023
    Breast Cancer, NCCN Guidelines Version 4.2022
  • NCCN, 2022
    Breast Cancer Screening and Diagnosis, NCCN, Version 1.2022
  • NICE, 2018
    Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)
  • NICE, 2018
    Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer, NICE, 2018
  • NCCN, 2014
    National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Breast Cancer (See 2022 Update)
  • NICE, 2013
    DG10 Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat: information for the public
  • AHRQ, 2013
    Technology Assessment on Genetic Testing or Molecular Pathology Testing of Cancers with Unknown Primary Site to Determine Origin (ARCHIVED)
  • NCCN, 2011
    NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

Consumer resources

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.